Clinical trialsCompany release

Oncolytics reports single-cell data on pelareorep immune activation in relapsed myeloma

🇺🇸 Oncolytics Biotech Inc (ONCY) · Mon 09 Nov 2026

Translational analysis from a Phase 1b/2 combination trial points to antigen-presenting activity and CD8 effector memory T-cell expansion, with a poster due at ASH on 12 December.

Oncolytics Biotech has announced translational single-cell sequencing data from a Phase 1b/2 trial of its oncolytic virus pelareorep in heavily pretreated relapsed or refractory multiple myeloma. Patients received pelareorep alongside bortezomib, dexamethasone and the PD-1 inhibitor pembrolizumab.

According to the company, the analysis showed enhanced antigen-presenting activity in myeloid cells and an increase in CD8 effector memory (EM) T cells. The company also reported that CD8 EM expansion was greater in patients who responded to treatment than in those who did not.

The findings are presented as evidence that pelareorep triggers an antiviral immune activation in this patient group. The summary available does not give response rates, patient numbers or other clinical outcome figures, so the data cannot yet be weighed against efficacy benchmarks in the setting.

The poster, Abstract 2183, will be presented at the American Society of Hematology Annual Meeting on 12 December 2026.

What it means for your team

  • The data are translational and biomarker-focused; no efficacy, safety or regulatory-pathway information was provided in the available material.
  • Teams tracking myeloma pipelines should look for the full ASH poster for patient numbers, response data and the statistical basis of the responder versus non-responder comparison.
  • The association between CD8 EM expansion and response is a mechanistic signal; whether it could serve as a biomarker would need confirmation in further studies.

Company's press release (SEC filing): Oncolytics Biotech Inc ↗

Article written by VigiEye from the official source (Oncolytics Biotech Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →